Compare · BIIB vs ENTX
BIIB vs ENTX
Side-by-side comparison of Biogen Inc. (BIIB) and Entera Bio Ltd. (ENTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and ENTX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $32.62B, about 54.1x ENTX ($603.2M).
- ENTX has been more active in the news (20 items in the past 4 weeks vs 9 for BIIB).
- BIIB has more recent analyst coverage (25 ratings vs 0 for ENTX).
- Company
- Biogen Inc.
- Entera Bio Ltd.
- Price
- -
- -
- Market cap
- $32.62B
- $603.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 20
- Recent ratings
- 25
- 0
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Latest BIIB
- LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
- LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
- Biogen upgraded by Wolfe Research with a new price target
- SEC Form 3 filed by new insider Parini Michael
- Biogen Completes Acquisition of RayThera Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Director Minor Lloyd sold $239,750 worth of shares (1,186 units at $202.15), decreasing direct ownership by 31% to 2,689 units (SEC Form 4)
- Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
- Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Biogen Inc.
Latest ENTX
- SEC Form S-3 filed by Entera Bio Ltd.
- SEC Form 3 filed by new insider Camisasca Riccardo Paolo
- Entera Bio Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events
- Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
- SEC Form D filed by Entera Bio Ltd.
- Director Rubin Steven D was granted 19,117 units of Ordinary Shares, increasing direct ownership by 127% to 34,117 units (SEC Form 4)
- Director Malca Yonatan was granted 22,815 units of Ordinary Shares, increasing direct ownership by 29% to 100,231 units (SEC Form 4)
- Director Taitel Haya was granted 20,790 units of Ordinary Shares, increasing direct ownership by 21% to 119,269 units (SEC Form 4)
- Director Ellis Sean was granted 20,034 units of Ordinary Shares, increasing direct ownership by 11% to 208,132 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Yaacov-Garbeli Dana